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Abstract:
As part of our ongoing study of the toxicity of compounds derived from 1,1-di(4-hydroxyphenyl)-2-ferrocenyl-but-1-ene, we recently showed that closely analogous [3] ferrocenophane complexes had an in vitro toxicity level substantially higher than that of their ferrocene counterparts, particularly in the case of mono-and diphenol complexes. In the current study we examined whether the presence of a dimethylamino chain, analogous to the chain in hydroxytamoxifen, was capable of producing in the ferrocenophane series the same antiestrogenic effect observed for OH- Tam revealed that the new complexes of [3] ferrocenophane have very strong antiproliferative effects; one of the compounds bearing an NHCO(CH2)2NMe2 chain has an IC50 value of 0.05 ± 0.02 M on MDA-MB-231 cells. All these complexes retain affinity for the estradiol receptor. At the low (nanomolar range) concentrations at which the estrogenic/antiestrogenic effect is expressed in these molecules, the presence of an amino side-chain does not induce in the [3] ferrocenophane series the antiestrogenic effect observed with OH-Tam and Fc-OHTam. However, this effect is found for the complex with a slightly longer chain (O(CH2)4NMe2).
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1-Introduction
Breast cancers remain the principal cause of cancer deaths in Europe causing almost 131,000 deaths in 2012. [1] About two-thirds of primary tumours, those classed as hormone-dependent (ER+) express the estradiol receptor and are stimulated by estrogens. Adjuvant treatment for this type of cancer most commonly includes prescription of antiestrogens (or SERMs, selective estrogen receptor modulators), molecules that can inhibit the growth of these tumours. Hydroxytamoxifen (OH-Tam 1; Figure 1 ), the reference antiestrogen, is administered in the form of tamoxifen citrate, the nonhydroxylated pro-drug. The mechanism of action of OH-Tam has been widely studied and extensively described. [2] Thanks to its phenol group, OH-Tam binds at the HBD (hormone binding site) of the estrogen receptor, but the presence of the long amino chain entails a significant modification at this level, namely the displacement of helix 12. This modified receptor binds as a dimer to the estrogen response element (ERE) of the DNA of ER+ cells, but does not permit recruitment of the co-factors necessary to activate DNA transcription. Thus low concentrations (10 nM) of OH-Tam produce a diminution in the proliferation of hormone-dependent breast cancer cells (MCF-7). However, since its effect is entirely linked to an interaction with the estrogen receptor, OHTam has no effect, at submicromolar concentration, on the growth of hormone-independent breast cancer cells, such as the triple negative breast cancer (TNBC) MDA-MB-231, which do not express the estrogen receptor. The two chief advantages of OH-Tam are thus its affinity for the estradiol receptor, and the presence of an amino chain that modifies the structure of the receptor such that cellular proliferation is significantly lowered. However, in the related acyclic ferrocifen series the presence of the "ferrocenyl-ene-phenol" unit triggers on cancer cells an additional cytotoxic effect that can be modulated by the basic amine chain. [3] We now describe this behavior in the ferrocenophane series.
Figure 1 : OH-Tamoxifen and several ferrocenyl and [3]ferrocenophane derivatives
We have shown that Fc-OH-Tam, 2, in which the phenyl group in hydroxytamoxifen, 1, has been replaced by a ferrocenyl substituent, has an antiproliferative effect in vitro on both hormone-dependent (MCF-7) and hormone-independent (MDA-MB-231) breast cancer cells. [3] [4] [5] [6] [7] In hormone-dependent cells this effect is essentially mediated by interaction with the estradiol receptor, and reversed by addition of estradiol. In contrast, the antiproliferative effect observed on hormone-independent cells such as MDA-MB-231 cells is a cytotoxic one. [8] This cytotoxic effect is also observed with the diphenol compound Fc-diOH, 3. [9] We have found that the most effective compounds (IC50 values less than 1 µM) possess, like 2 and 3, a ferrocene-ene-paraphenol entity. [10, 11] The ferrocene appears to act as a stimulus for a mild intramolecular oxidation involving the phenol group, leading to the facile production of quinone methides whose formation, structure and electrophilic behaviour we have established. [12] [13] [14] [15] A Structure-Activity Relationship (SAR) study extended to include a number of ferrocene complexes has allowed us to identify another molecule, the cyclic diphenol 4 derived from [3] ferrocenophane, whose toxicity on MDA-MB-231 cells is noticeably greater than that of Fc-diOH (IC50 values of 0.09 M for 4 versus 0.6 µM for 3). [16] In addition, the toxicity of the two diphenols 3 and 4 has been tested on the panel of 60 cell lines of the National Cancer Institute (Bethesda, MD, USA). The results show that the [3] ferrocenophane 4 is more toxic overall than Fc-diOH, 3 (mean IC50 values are 0.18 and 0.52 µM, respectively). The activity profiles of these compounds also show that 3 and 4 probably do not share the same mechanism of action either with each other or with the 171 reference molecules in the database, and in particular that they do not act, like cisplatin, via an alkylation of DNA. [17] The diphenol 4 possesses, like 3, a moderate level of affinity for the estradiol receptor.
As a result, both show a proliferative effect at low concentrations (10 -8 M) on hormonedependent MCF-7 cells, that partially offsets the cytotoxic effect caused by the oxidation of the ferrocene. To better understand the effect of the side chain on the antiproliferative activity of ferrocene and [3] ferrocenophane derivatives, several new compounds containing an amino chain have been synthesized and studied for their cytotoxic and their estrogenic/antiestrogenic effects. The first such molecule was compound 7; subsequently, we prepared the analogous complexes of pyrrolidine, 10, of piperidine, 11, and also molecule 14 which contains an -O(CH2)4N(CH3)2 unit. Interestingly, it has recently been reported that the presence of an amide function on the basic chain of certain SERMs modified their properties by preventing their recognition by the estrogen receptor. [18] We therefore prepared complex 12, bearing the chain containing an NHCO(CH2)2NMe2 amide function. Since we also found that replacement of the OH groups in 4 by NH2 or H gave cytotoxic products (5 and 6), we also synthesized complexes 8, 9 and 13 that possessed alkoxyamino chains, but no hydroxyl units. Finally, to allow direct comparison between the ferrocene and ferrocenophane series, the ferrocene complexes 15 and 16 were synthesized. In total, ten new complexes, listed in Figure 2 , were synthesized and studied. 
2-1-1 Synthesis of the complexes with a dimethylaminopropyl chain 7 -9
Compounds 7, 8 and 9 were synthesized in a one-step reaction starting from 4, 17 and 18 by alkylation of the hydroxyl group (Scheme 1). Sodium hydride was used to generate the corresponding phenolate from each of these compounds which, when heated with 3-dimethylamino-1-propyl hydrochloride in DMF at 80°C for 12 hours, furnished 7, 8 and 9 in 27%, 66% and 83% yields, respectively. All the products were obtained as mixtures of (E+Z) isomers in various proportions (see Experimental Section). [19] , 22 [20] , 23 [17] and 24 [21] (Scheme 4). The amino function was first transformed into a chloroamido chain by reaction of 3-chloropropionylchloride in the presence of pyridine as a base; in these cases, the acyl chloride reacts exclusively on the amino function. The [3] ferrocenophane chloro compounds 25 and 26 were obtained in high yields (88%, 98%), while the yields of the ferrocenyl chloro compounds 27 and 28 were only moderate (44% and 39%, respectively). Amination of the chloro compounds was carried out by heating a solution of each of the compounds in methanol containing dimethylamine at 60 °C. All compounds were obtained in high yields, 89-97%, as a mixture of E and Z isomers. To establish the identity of a typical example of one the new compounds unequivocally, the X-ray crystal structure of Z-1-[ (4-(3-chloropropionyl) aminophenylphenyl)-methylidene]- [3] ferrocenophane, 26, was determined. Crystallization from acetonitrile of the E+Z mixture gave a suitable sample of the Z isomer whose structure is shown in Figure 3 . The geometry of the [3] ferrocenophane moiety in 26 closely resembles those reported previously. [19, 22] The system crystallizes with two independent molecules in the unit cell. As expected, the three-carbon bridge between the two cyclopentadienyl rings is too short for them to maintain their coplanarity, and the dihedral angles between the ring planes in the independent molecules are 9.5° and 10°. The Fe-CCp distances range from 2.028(11) to 2.084 (14) , and the bond lengths in the three-carbon bridge are C1-C11 = 1.509 (13) , C11-C12 = 1.507(11), C12-C13 = 1.559 (14) , and C13-C6 = 1.509 (14) . The aryl rings attached to C14
are oriented almost orthogonally to each other; the dihedral angle between these ring planes is 80°. Full crystallographic data are provided as Supplementary Information. 
Biological Results
The biological effects of the newly synthesized complexes were studied and compared to those of two reference compounds, 2 and 4. Four types of experiments were carried out: (1) study of the antiproliferative effect on MDA-MB-231 cells, hormone-independent cells which allow the cytotoxicity of the molecules to be tested; (2) determination of Relative Binding Affinity (RBA) values for these compounds, to establish whether or not they possess an affinity for the estradiol receptor; (3) study of the proliferative/antiproliferative effect of these complexes on hormone-dependent MCF-7 cells at low concentrations (in the nanomolar range), to ascertain whether the addition of a long side chain reveals antiestrogenic effects, (4) measurement of the lipophilicity of the complexes.
Study of the antiproliferative effect of the complexes on hormone-independent

MDA-MB-231 cells
The IC50 values of the new compounds 7-16 for the MDA-MB-231 cancer cells are collected in Table 1 . The lipophilicity of these four compounds does not appear to play an important role. Once again, it demonstrates that systems lacking an OH group, as in 9, 13 and 16, are less active than their analogues that do possess it. Substitution of the amino chain -O(CH2)3NMe2 by the amido chain -NHCO(CH2)2NMe2 produces different effects. Compounds 9 and 13 have almost the same IC50 value, but the amido compound 12 is three times more active than 7
(0.05 M versus 0.18 M). At present therefore, molecule 12 is one of the three most efficacious of all the ferrocenyl derivatives that we have prepared. [17] For comparison, we have also included the IC50 values for molecules 29 and 30 that were synthesized previously; [23] these latter compounds are less effective than compounds 12 et 13. The lengthening of the amido chain may be the cause of their diminished activity.
Globally, molecules in the ferrocenophane series are more active than their ferrocene counterparts; to be precise, compounds 4, 7, 12 and 13 are, respectively, 7, 3, 13 and 3 times better than compounds 3, 2, 15 and 16. We recently shown that enzymatic oxidation of 4, the most studied complex in the ferrocenophane series, leads to the formation of a transient shortlived species attributed to a quinone methide radical. [24] On the contrary, the enzymatic oxidation of the ferrocenyl complexes 2 or 3 leads to the formation of quinone methides. [25] Reactivity of a radical is expected to be higher than that of the quinone methide and could explain the higher cytotoxicity of the ferrocenophane complexes. Substitution of the amino chain of 4 by an amido chain gives access to 12, the most cytotoxic complex of the series. The precise role of this amido chain has not yet been elucidated and will be the subject of further study.
Relative binding affinity values for the alpha form of the estrogen receptor (ER)
and LogPo/w of the compounds
The relative binding affinity values (RBA) of the compounds were measured for the alpha form of the estrogen receptor and are reported in Table 1 . All the complexes showed a significant affinity for the estrogen receptor, even those lacking an OH substituent. There is no clear difference between the ferrocenophane and the ferrocenyl complexes. The RBA values found for the disubstituted complexes possessing an amino side chain plus another substituent (OH or NH2) are high (between 10-23%), the highest value being obtained for 15, the ferrocenyl derivatives with the NHCO(CH2)2NMe2 side-chain. Finally, values of around 4% were found for the three mono substituted complexes bearing only an amino chain.
The lipophilicity values obtained for the different complexes are shown in Table 1 .
These values are very close for the three ferrocene complexes (4.3 -4.6) while varying significantly for the ferrocenophane complexes (2.4 -4.7). In addition, the logPo/w values of the ferrocene complexes are always higher than those of their ferrocenophane counterparts.
Finally, complexes 9 and 12 have lipophilicity values very close to those of estradiol (3.5) and OH-Tam (3.2 and 3.4).
[3]
Estrogenic/antiestrogenic effect of the complexes in vitro on MCF-7 cells
The effect of the new complexes on the growth of MCF-7 hormone dependent cells was then studied and the results are shown in Figure 4 . The characteristic proliferative effect of estradiol is observed, and it is clearly evident that the behavior of the complexes of the ferrocenophane family differs from that of the ferrocenyls. In the case of the ferrocene complexes 15 and 16 an antiproliferative effect is observed analogous to that observed earlier for Fc-OH-Tam, which is attributed to an antiestrogenic effect. This effect is not found in the ferrocenophane series. Instead a slight estrogenic effect is observed in the complexes of this series for 7, 8, 12 and 13, but not for 9 which shows no effect. This result appears to show that the constraint imposed by the presence of a carbon chain linking the two ferrocene rings prevents the expression of the antiestrogenic effect produced by the presence of the long dimethylamino chain in OH- Tam We then decided to take a closer look at the estrogenic/antiestrogenic effects of compounds 7 and 14 which differ only in the length of their aminated chain. Figure 5 shows the effect of these two complexes on MCF-7 at 3 concentrations (1, 10, 100 nM). At 1 nM compound 7 provokes an estrogenic effect; this effect diminishes at 10 nM and inverts at 100 nM, without doubt because of the appearance of the cytotoxic effect. By way of contrast, for compound 14 the antiestrogenic effect has already been evident from 1 nM. This result can perhaps be explained by the lengthening of the amino chain, from three to four methylenes, which allows the molecule to bind better with the antiestrogenic conformation of the receptor site, as verified by the modelling study below.
Molecular modeling
Molecular docking experiments using the crystal structure of the ligand binding domain (LBD) of human ER (hER) as described by Shiau and al. [27] were performed using the program Spartan 14. [28] Only the amino acids that constitute the wall of the cavity have been retained. The organic molecule was removed from the cavity and replaced successively with the organometallic bio-ligands. Only Z isomers were calculated since it had previously been shown that the Z form of ferrocifen 2 shows better recognition for the receptor. [3] Energy minimisation was then carried out using the Merck molecular force field (MMFF) with the heavy atoms (non-hydrogen) of the amino acids of the cavity wall immobilised, then the geometry was optimized using quantum mechanical semi-empirical PM3 methods. This allowed the ideal positions of the bio-ligands to be determined. Quantum mechanical semiempirical PM3 methods were then used to determine the affinity of the bio-ligands for the cavity. This requires calculation of the energies of bio-ligand cavity group, of the cavity itself, and of the ligand, the latter two in the conformations they had in the molecular assemblies to
give the rH° enthalpy variations of the reactions: bio-ligand + cavity → molecular assembly (Table 2 ).
For the two compounds, binding to the ER is thermodynamically favoured, as evidenced by the negative enthalpy of formation for the ligand-receptor complex. The most negative value for 14 shows better affinity for the cavity than 7. Moreover, the calculations reveal a higher possibility for a hydrogen bond between the proton on the carboxylic moiety of the aspartic acid Asp 351 and the nitrogen atom of the bio-ligand for 14 than for 7. The distances O-H…N-are 1.91 and 2.81 Å respectively and the optimised distance is shown in For clarity, the bioligands and three important amino acids are shown as ball and spoke while other amino acids appear as stick representations.
Conclusions
The synthesis of novel complexes in the ferrocene and ferrocenophane series with amino side-chains has produced molecules with very clear cytotoxic effects on MDA-MB-231 hormone-independent breast cancer cells. The mechanistic particularity of 4, the most studied complex in the ferrocenophane series, has recently been disclosed and is associated with an active radical intermediate. [24] All the complexes in the series retain an affinity for the estrogen receptor, but only those of the acyclic ferrocenyl series express an antiestrogenic effect analogous to that of OH-Tam on hormone-dependent MCF-7 cells. This effect is not found in their analogs in the ferrocenophane series except for 14. Actually it is possible to turn the estrogenic effect into an antiestrogenic one by lengthening the amino chain (as in the case of 7 and 14). However, it is noteworthy that compound 9 is neutral in this respect. At this time, where the issue of SERMs that act as endocrine disrupters is the focus of serious examination, these results illustrate the subtlety of the effects, and emphasise the care that one must bring to their analysis.
Experimental Section
General Remarks. THF was obtained by distillation from sodium/benzophenone. Thin layer chromatography was performed on silica gel 60GF254. The preparative HPLC separations were performed on a Shimadzu apparatus with a Nucleodur C18 column (length 25 cm, diameter 3.2 cm, and particle size 10 mm) using acetonitrile or acetonitrile/water as an eluent.
Column chromatography purifications were performed by using silica gel with appropriate eluent. The analytical HPLC controls were performed on a Shimadzu apparatus with a Nucleodur C18 column (length 15 cm, diameter 0.45 cm, and particle size 5 µm) using acetonitrile as an eluent. 1 H and 13 C NMR spectra were recorded on a 300 MHz Bruker spectrometer. Mass spectrometry was performed with a Nermag R 10-10C spectrometer. 
General Procedure 1: Alkylation of phenol groups
In each case, the appropriate compound was dissolved in DMF and sodium hydride was added. The mixture was stirred for 10 min, 3-dimethylamino-1-propyl chloride hydrochloride was added and the mixture heated at 90°C overnight. Additional 3-dimethylamino-1-propyl chloride hydrochloride was then added, and heating was continued for 4 hours. The mixture was cooled and concentrated under reduced pressure, the residue was dissolved in dichloromethane and was washed twice with a diluted aqueous solution of sodium hydroxide, followed with water. After drying over magnesium sulphate, the solution was concentrated under reduced pressure and the residue was chromatographed on silica gel with a 4/1 solution of chloroform/triethylamine as eluent. The residue was recrystallized from appropriate solution to yield the product. 
1-[(4-(3-Dimethylaminopropoxy)phenyl-phenyl)methylidene]-[3]ferrocenophane, 9.
Analogously, 18 (500 mg, 1. mL of DMF were treated as described above. After purification by column chromatography with acetone / NEt3 (10/1) eluent system and then recrystallization from diethyl ether, 9 (500 mg, 83%) was obtained as a bright yellow product as a mixture of E and Z isomers (94/6).
The major isomer was identified as the Z form. 1 prepared previously by using another synthetic procedure and tested for its antiplasmodial activity. [29] General procedure 2: Preparation of compounds 7 (second method), 10, 11. Titanium chloride (4.66 g, 2.7 mL, 24.6 mmol) was added dropwise to a suspension of zinc powder (2.41 g, 36.8 mmol) in 100 mL of dry THF at 10-20°C and the mixture was heated at reflux for 2 h. A second solution was prepared by dissolving [3] ferrocenophan-1-one (1.47 g, 6.14 mmol) and bromo compound 19 (2.06 g, 6.14 mmol) in 25 mL of dry THF. This latter solution was added dropwise to the first solution and then the reflux was continued overnight.
After cooling to room temperature, the mixture was stirred with water and dichloromethane.
The mixture was acidified with diluted hydrochloric acid until the dark color disappeared and was decanted. The aqueous layer was extracted with dichloromethane and the combination of This crude compound was used without further purification in the second step. It was transferred into a pressure tube and a solution of amine in methanol (60 mmol of amine) was added. The pressure tube was heated at 60°C for 24 hours, then cooled to room temperature.
The work-up was done depending on the amine.
1-[(4-(3-Dimethylaminopropoxy)phenyl-4-hydroxyphenyl)methylidene]-[3]ferroceno-
phane, 7 (second method). Dimethylamine in methanol (2 M, 30 mL, 60 mmol) was commercially available. The mixture was concentrated under reduced pressure and the residue was chromatographed on a silica gel column with acetone, then acetone/triethylamine 10/1 as the eluents. After concentration under reduced pressure, the residue was recrystallized from acetone to obtain yellow crystals of 7 (yield 21%). 3-(N-pyrrolidinyl) 
1-[(4-(
1-[(4-(3-(N-piperidinyl)propoxy)phenyl-4-hydroxyphenyl)methylidene]-
[3]ferrocenophane, 11. The solution of piperidine was made up with 5.22 g of piperidine in
15 mL of methanol. The compound 11 precipitated and was simply filtered off to recover 1.23 g (yield : 37%) as a mixture of Z and E isomers (90/10). 1 H NMR (DMSO-d6, 300 MHz): δ. 
General Procedure 3: Acylation of aniline groups
In a Schlenk flask, the appropriate ferrocenyl amino compound was dissolved in 30 mL of anhydrous THF. Appropriate acetyl chloride derivatives and pyridine were added and the reaction mixture was left to stir at room temperature for 3 hours. The mixture was poured into water and extracted with dichloromethane. The organic layer was washed with water, dried over magnesium sulphate, filtered, and concentrated under reduced pressure. The crude mixture was filtered over silica gel using petroleum ether and CH2Cl2, concentrated under reduced pressure, and purified by HPLC (acetonitrile/H2O). Then, recrystallization from appropriate solvent systems formed desired products as crystals consisting of a mixture of Z and E isomers. 
1-[(4-(3-chloropropionyl)aminophenyl)-(4-hydroxyphenyl)methylidene]-[3]ferroceno-
1-[(4-(3-chloropropionyl)aminophenyl-phenyl)-methylidene]-[3]ferrocenophane, 26.
Analogously 
General Procedure 4: Dimethylamination
In a pressure tube, the appropriate 3-chloropropionylamino compound was dissolved in 2.0 M dimethylamine solution in methanol. The reaction mixture was heated to 60° C with stirring for 1 day. The mixture was concentrated under reduced pressure, a saturated solution of NaHCO3 and dichloromethane were added and, after decantation, the organic layer was washed with water, dried on magnesium sulfate and concentrated under reduced pressure. The crude mixture was purified by flash column chromatography (Acetone/Et3N: 10 / 1); some were recrystallized from appropriate solvent system to yield a mixture of Z and E isomers. full-matrix least-squares technique on F 2 using the CRYSTALS programs. [30] All nonhydrogen atoms were refined anisotropically. All hydrogen atoms were set in calculated positions and isotropically refined. The values of the discrepancy indices R1 (Rw2) were 0.079 (0.262). The final Flack [31] parameter is 0.45 ( 
1-[(4-(3-dimethylaminopropionyl)aminophenyl)-(4-hydroxyphenyl)methylidene]-
